340 related articles for article (PubMed ID: 34405005)
21. Benefits of Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphoma.
Zhou W; Chen W; Wan X; Luo C; Du X; Li X; Chen Q; Gao R; Zhang X; Xie M; Wang M
Front Genet; 2021; 12():815679. PubMed ID: 35126471
[No Abstract] [Full Text] [Related]
22. Intensive Debulking Chemotherapy Improves the Short-Term and Long-Term Efficacy of Anti-CD19-CAR-T in Refractory/Relapsed DLBCL With High Tumor Bulk.
Lyu C; Cui R; Wang J; Mou N; Jiang Y; Li W; Deng Q
Front Oncol; 2021; 11():706087. PubMed ID: 34395279
[TBL] [Abstract][Full Text] [Related]
23. [Roles of PET/CT in Predicting the Prognosis of Diffuse Large B Cell Lymphoma Patients Treated with Chimeric Antigen Receptor T Cell Therapy].
Zheng XQ; Ding CY; Zou YX; Zhu HY; Wang L; Fan L; Xu W; Li JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Aug; 28(4):1189-1196. PubMed ID: 32798397
[TBL] [Abstract][Full Text] [Related]
24. Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma.
Sang W; Shi M; Yang J; Cao J; Xu L; Yan D; Yao M; Liu H; Li W; Zhang B; Sun K; Song X; Sun C; Jiao J; Qin Y; Sang T; Ma Y; Wu M; Gao X; Cheng H; Yan Z; Li D; Sun H; Zhu F; Wang Y; Zeng L; Li Z; Zheng J; Xu K
Cancer Med; 2020 Aug; 9(16):5827-5838. PubMed ID: 32608579
[TBL] [Abstract][Full Text] [Related]
25. Risk profiling of patients with relapsed/refractory diffuse large B-cell lymphoma by measuring circulating tumor DNA.
Herrera AF; Tracy S; Croft B; Opat S; Ray J; Lovejoy AF; Musick L; Paulson JN; Sehn LH; Jiang Y
Blood Adv; 2022 Mar; 6(6):1651-1660. PubMed ID: 35086141
[TBL] [Abstract][Full Text] [Related]
26. Sequential anti-CD19, 22, and 20 autologous chimeric antigen receptor T-cell (CAR-T) treatments of a child with relapsed refractory Burkitt lymphoma: a case report and literature review.
Du J; Zhang Y
J Cancer Res Clin Oncol; 2020 Jun; 146(6):1575-1582. PubMed ID: 32222815
[TBL] [Abstract][Full Text] [Related]
27. Case report: Differential diagnosis of highly amplified anti-CD5 CAR T cells and relapsed lymphoma cells in a patient with refractory ALK positive anaplastic large cell lymphoma.
Mu W; Zhang M; Hu G; Han Y; Mao X; Chen C; Shen K; Dai Z; Zhu X; Zhou X; Huang L; Ao Q; Xiao M
Front Immunol; 2023; 14():1280007. PubMed ID: 38143760
[TBL] [Abstract][Full Text] [Related]
28. Therapeutic effects of chimeric antigen receptor T cells (CAR-T) on relapse/refractory diffuse large B-cell lymphoma (R/R DLBCL): a meta-analysis.
Cao HH; Wang LL; Geng CK; Mao WW; Yang LL; Ma Y; He M; Zhang R; Zhou YY; Liu LQ; Hu XJ; Yu JX; Yang L; Shen XF; Yin LF; Gu XZ; Shen ZL
Eur Rev Med Pharmacol Sci; 2020 May; 24(9):4921-4930. PubMed ID: 32432755
[TBL] [Abstract][Full Text] [Related]
29. Circulating tumor DNA determining hyperprogressive disease after CAR-T therapy alarms in DLBCL: a case report and literature review.
He J; Zou R; Kang L; Yu L; Wang P; Shao Y; Liang J; Wu D; Jin Z; Qu C
Front Oncol; 2023; 13():1283194. PubMed ID: 38090479
[TBL] [Abstract][Full Text] [Related]
30. Circulating tumor DNA adds specificity to PET after axicabtagene ciloleucel in large B-cell lymphoma.
Dean EA; Kimmel GJ; Frank MJ; Bukhari A; Hossain NM; Jain MD; Dahiya S; Miklos DB; Altrock PM; Locke FL
Blood Adv; 2023 Aug; 7(16):4608-4618. PubMed ID: 37126659
[TBL] [Abstract][Full Text] [Related]
31.
Chen L; Mu W; Gu J; Xiao M; Huang L; Zheng M; Li C; Xiao Y; Zhou J; Long X
Diagnostics (Basel); 2021 May; 11(5):. PubMed ID: 34066756
[TBL] [Abstract][Full Text] [Related]
32. Indicators describing the tumor lesion aggregation and dissemination and their impact on the prognosis of patients with diffuse large B cell lymphoma receiving chimeric antigen receptor T cell therapy.
Dang X; Li P; Shen A; Lu Y; Zhu Z; Zhang M; Qian W; Liang A; Zhang W
Cancer Med; 2024 Mar; 13(6):e6991. PubMed ID: 38506226
[TBL] [Abstract][Full Text] [Related]
33. Anti-CD19 chimeric antigen receptor-modified T-cell therapy bridging to allogeneic hematopoietic stem cell transplantation for relapsed/refractory B-cell acute lymphoblastic leukemia: An open-label pragmatic clinical trial.
Jiang H; Li C; Yin P; Guo T; Liu L; Xia L; Wu Y; Zhou F; Ai L; Shi W; Lu X; Wang H; Tang L; Wei Q; Deng J; Jin R; Xiong W; Dong J; Mei H; Hu Y
Am J Hematol; 2019 Oct; 94(10):1113-1122. PubMed ID: 31321805
[TBL] [Abstract][Full Text] [Related]
34. Dual specific CD19/CD22-targeted chimeric antigen receptor T-cell therapy for refractory diffuse large B-cell lymphoma: A case report.
Huang C; Zhang HC; Ho JY; Liu RX; Wang L; Kuang N; Zheng MR; Liu LH; Li JQ
Oncol Lett; 2020 Oct; 20(4):21. PubMed ID: 32774494
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia.
Gu R; Liu F; Zou D; Xu Y; Lu Y; Liu B; Liu W; Chen X; Liu K; Guo Y; Gong X; Lv R; Chen X; Zhou C; Zhong M; Wang H; Wei H; Mi Y; Qiu L; Lv L; Wang M; Wang Y; Zhu X; Wang J
J Hematol Oncol; 2020 Sep; 13(1):122. PubMed ID: 32894185
[TBL] [Abstract][Full Text] [Related]
36. Case Report: Subtotal Lymphoid and Total Marrow Irradiation as Bridge Therapy to CD19-Directed CAR T Cells in a Chemorefractory DLBCL With Leukemic Involvement.
Saldi S; Perriello VM; Falini L; Ruggeri L; Fulcheri C; Ciardelli S; Innocente A; Ballanti S; Baffa N; Flenghi L; Pierini A; Aristei C; Falini B
Front Immunol; 2022; 13():934700. PubMed ID: 35911683
[TBL] [Abstract][Full Text] [Related]
37. Chidamide and sintilimab combination in diffuse large B-cell lymphoma progressing after chimeric antigen receptor T therapy.
Hao YY; Chen PP; Yuan XG; Zhao AQ; Liang Y; Liu H; Qian WB
World J Clin Cases; 2022 Jul; 10(19):6555-6562. PubMed ID: 35979312
[TBL] [Abstract][Full Text] [Related]
38. Targeted Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Tafasitamab in Context.
Abdulhaq H; Hwang A; Mahmood O
Onco Targets Ther; 2023; 16():617-629. PubMed ID: 37492075
[TBL] [Abstract][Full Text] [Related]
39. The European Medicines Agency Review of Kymriah (Tisagenlecleucel) for the Treatment of Acute Lymphoblastic Leukemia and Diffuse Large B-Cell Lymphoma.
Ali S; Kjeken R; Niederlaender C; Markey G; Saunders TS; Opsata M; Moltu K; Bremnes B; Grønevik E; Muusse M; Håkonsen GD; Skibeli V; Kalland ME; Wang I; Buajordet I; Urbaniak A; Johnston J; Rantell K; Kerwash E; Schuessler-Lenz M; Salmonson T; Bergh J; Gisselbrecht C; Tzogani K; Papadouli I; Pignatti F
Oncologist; 2020 Feb; 25(2):e321-e327. PubMed ID: 32043764
[TBL] [Abstract][Full Text] [Related]
40. Circulating Tumor DNA to Monitor Therapy for Aggressive B-Cell Lymphomas.
Kwok M; Wu SP; Mo C; Summers T; Roschewski M
Curr Treat Options Oncol; 2016 Sep; 17(9):47. PubMed ID: 27461036
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
